TY - JOUR
T1 - Paediatric porphyria and human hemin
T2 - A treatment challenge in a lower middle income country
AU - Fatima, Syeda Anum
AU - Jurair, Humaira
AU - Abbas, Qalab
AU - Rehman, Arshalooz Jamila
N1 - Publisher Copyright:
© © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/1/8
Y1 - 2020/1/8
N2 - Here, we report a case of a 15-year-old girl who presented to the emergency department with symptoms of abdominal pain, nausea, vomiting and seizures. She was diagnosed with acute intermittent porphyria. Treatment was started by removing all porphogenic drugs, providing high glucose intake (oral and intravenous), which initially resulted in good clinical outcomes. However, she deteriorated again and also developed neurological manifestation (paraplegia) for which she required mechanical ventilation because of acute respiratory failure. This time she was initiated on human hemin for four consecutive days. After 2 days of therapy, her porphobilinogen levels decreased to 50% of the initial raised value. Increased lactic acid and blood urea nitrogen were the two side effects observed after the treatment, with no apparent signs of acute kidney injury. To the best of our knowledge, in paediatric population, this is the first reported case of treatment of acute intermittent porphyria with human hemin in Pakistan.
AB - Here, we report a case of a 15-year-old girl who presented to the emergency department with symptoms of abdominal pain, nausea, vomiting and seizures. She was diagnosed with acute intermittent porphyria. Treatment was started by removing all porphogenic drugs, providing high glucose intake (oral and intravenous), which initially resulted in good clinical outcomes. However, she deteriorated again and also developed neurological manifestation (paraplegia) for which she required mechanical ventilation because of acute respiratory failure. This time she was initiated on human hemin for four consecutive days. After 2 days of therapy, her porphobilinogen levels decreased to 50% of the initial raised value. Increased lactic acid and blood urea nitrogen were the two side effects observed after the treatment, with no apparent signs of acute kidney injury. To the best of our knowledge, in paediatric population, this is the first reported case of treatment of acute intermittent porphyria with human hemin in Pakistan.
KW - nutritional support
KW - paediatrics (drugs and medicines)
KW - pharmacology and therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85077691631&partnerID=8YFLogxK
U2 - 10.1136/bcr-2019-232236
DO - 10.1136/bcr-2019-232236
M3 - Article
C2 - 31919062
AN - SCOPUS:85077691631
SN - 1757-790X
VL - 13
JO - BMJ Case Reports
JF - BMJ Case Reports
IS - 1
M1 - e232236
ER -